Showing results (111-120 of 192) with videos related to

Sort By:
Pageof 20
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2011
First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemiaEric J Feldman, Jeffrey E Lancet, Jonathan E Kolitz, et al.
Leukemia Research|November 27, 2010
Salvage chemotherapy regimens for acute myeloid leukemia: Is one better? Efficacy comparison between CLAG and MEC regimensSamantha L Price, Jeffrey E Lancet, Timothy J George, et al.
British Journal of Haematology|October 14, 2009
Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemiaThomas R Chauncey, Holly Gundacker, Mazyar Shadman, et al.
Blood|July 20, 2007
Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromesAzim Mohamedali, Joop Gäken, Natalie A Twine, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 5, 2019
A Phase II Study to Determine the Safety and Efficacy of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase (IDO) Enzyme INCB024360 in Patients with Myelodysplastic SyndromesRami S Komrokji, Sheng Wei, Adam W Mailloux, et al.
Haematologica|February 4, 2014
A phase II multicenter rabbit anti-thymocyte globulin trial in patients with myelodysplastic syndromes identifying a novel model for response predictionRami S Komrokji, Adam W Mailloux, Dung-Tsa Chen, et al.
Leukemia Research|September 3, 2013
Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignanciesDeepa Sampath, Asifa Malik, William Plunkett, et al.
Haematologica|March 6, 2016
Prospective international validation of the Quality of Life in Myelodysplasia Scale (QUALMS)Gregory A Abel, Fabio Efficace, Rena J Buckstein, et al.
Blood Advances|February 16, 2021
Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromesAnthony M Hunter, Rami S Komrokji, Seongseok Yun, et al.
British Journal of Haematology|February 22, 2011
Identification of a risk dependent microRNA expression signature in myelodysplastic syndromesLubomir Sokol, Gisela Caceres, Stefano Volinia, et al.
Pageof 20